A peripherally restricted cannabinoid receptor agonist produces robust anti-nociceptive effects in rodent models of inflammatory and neuropathic pain

@article{Yu2010APR,
  title={A peripherally restricted cannabinoid receptor agonist produces robust anti-nociceptive effects in rodent models of inflammatory and neuropathic pain},
  author={X. H. Yu and C. Cao and G. Martino and C. Puma and A. Morinville and S. St-Onge and {\'E}. Lessard and M. Perkins and J. Laird},
  journal={PAIN{\textregistered}},
  year={2010},
  volume={151},
  pages={337-344}
}
&NA; Cannabinoids are analgesic in man, but their use is limited by their psychoactive properties. One way to avoid cannabinoid receptor subtype 1 (CB1R)‐mediated central side‐effects is to develop CB1R agonists with limited CNS penetration. Activation of peripheral CB1Rs has been proposed to be analgesic, but the relative contribution of peripheral CB1Rs to the analgesic effects of systemic cannabinoids remains unclear. Here we addressed this by exploring the analgesic properties and site of… Expand
The cannabinoid agonist CB-13 produces peripherally mediated analgesia in mice but elicits tolerance and signs of CNS activity with repeated dosing
TLDR
Significant caution is warranted regarding therapeutic use of CB-13 with the goal of avoiding CNS side effects, but the clear analgesic effect of acute peripheral CB1 receptor activation suggests that peripherally restricted cannabinoids are a viable target for novel analgesic development. Expand
Peripherally Selective Cannabinoid 1 Receptor (CB1R) Agonists for the Treatment of Neuropathic Pain.
TLDR
Indole and indene compounds engineered for high hCB1R affinity, peripheral selectivity, metabolic stability, and in vivo efficacy hold promise as a viable treatment for neuropathic pain. Expand
Peripheral interactions between cannabinoid and opioid receptor agonists in a model of inflammatory mechanical hyperalgesia
TLDR
The findings showed that MOR and CB1 agonists directed at the inflamed site effectively attenuate mechanical hyperalgesia when administered individually, but exert opposing effects when administered together, suggesting distinct mechanisms unique to peripheral nociceptors or inflamed tissue. Expand
Involvement of central and peripheral cannabinoid receptors on antinociceptive effect of tetrahydrocannabinol in muscle pain.
TLDR
This study suggests that tetrahydrocannabinol (THC), a cannabinoid natural derivative with therapeutic use in humans, could be a future pharmacological option in the treatment of muscle pain and the local administration of THC could be an interesting option to treat this type of pain avoiding the central adverse effects. Expand
Targeting Peripherally Restricted Cannabinoid Receptor 1, Cannabinoid Receptor 2, and Endocannabinoid-Degrading Enzymes for the Treatment of Neuropathic Pain Including Neuropathic Orofacial Pain
TLDR
This review will discuss the above-mentioned alternative approaches that show potential for treating neuropathic pain including NOP, including inhibition of degradation of a major endocannabinoid, 2-arachydonoylglycerol, which can attenuate NOP following trigeminal nerve injury in mice. Expand
Effects of gonadal hormones on the peripheral cannabinoid receptor 1 (CB1R) system under a myositis condition in rats
TLDR
It is indicated that testosterone, but not estradiol, is required for the regulation of CB1Rs in TG under inflammatory conditions, which provides explanations for the sex differences in the antihyperalgesic effects of peripherally administered cannabinoids. Expand
Recent development of CB2 selective and peripheral CB1/CB2 cannabinoid receptor ligands.
TLDR
This review focuses on the recent literature dealing with selective CB2 receptor ligands, with a particular emphasis on the CB2 agonists developed from 2009 onwards. Expand
Cannabinoids in pain management: CB1, CB2 and non-classic receptor ligands
  • Mellar P. Davis
  • Chemistry, Medicine
  • Expert opinion on investigational drugs
  • 2014
TLDR
Most clinically productive development of cannabinoids over the next 5 years will be in the area of selective CB2r agonists, which will be tested in various inflammatory, osteoarthritis and neuropathic pains. Expand
Functional characterization and analgesic effects of mixed cannabinoid receptor/T-type channel ligands
TLDR
The results reveal that a set of novel cannabinioid receptor ligands potently inhibit T- type calcium channels and show analgesic effects in vivo, and suggest possible novel means of mediating pain relief through mixed T-type/cannabinoid receptor ligANDs. Expand
Zerumbone Ameliorates Neuropathic Pain Symptoms via Cannabinoid and PPAR Receptors Using In Vivo and In Silico Models
TLDR
The findings indicated the involvement of CB1, PPARα and PPARγ in zerumbone’s action against mechanical allodynia, whereas only CB1 andPPARα were involved against thermal hyperalgesia. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 36 REFERENCES
Cannabinoids mediate analgesia largely via peripheral type 1 cannabinoid receptors in nociceptors
TLDR
It is concluded that the contribution of CB1-type receptors expressed on the peripheral terminals of nociceptors to cannabinoid-induced analgesia is paramount, which should enable the development of peripherally acting CB1 analgesic agonists without any central side effects. Expand
The role of central and peripheral Cannabinoid1 receptors in the antihyperalgesic activity of cannabinoids in a model of neuropathic pain.
TLDR
Cannabinoids are highly potent and efficacious antihyperalgesic agents in a model of neuropathic pain and are likely to be mediated via an action in the CNS and in the periphery. Expand
Cannabinoids reduce hyperalgesia and inflammation via interaction with peripheral CB1 receptors
TLDR
The results indicate that cannabinoids reduce inflammation via interaction with a peripheral CB1 receptor, and a potential mechanism for this effect is the inhibition of neurosecretion from capsaicin‐sensitive primary afferent fibers. Expand
Antihyperalgesic properties of the cannabinoid CT-3 in chronic neuropathic and inflammatory pain states in the rat
TLDR
Data show that CT‐3 is a cannabinoid receptor agonist and is efficacious in animal models of chronic pain by activation of the CB1 receptor, and exhibits a superior therapeutic index compared to other cannabinoid compounds, which may reflect a relatively reduced CNS penetration. Expand
The synthetic cannabinoid WIN55,212‐2 attenuates hyperalgesia and allodynia in a rat model of neuropathic pain
TLDR
The data indicate that cannabinoids may have therapeutic potential in neuropathic pain, and that this effect is mediated through the CB1 receptor. Expand
A peripheral cannabinoid mechanism suppresses spinal fos protein expression and pain behavior in a rat model of inflammation
TLDR
Data provide direct evidence that a peripheral cannabinoid mechanism suppresses the development of inflammation-evoked neuronal activity at the level of the spinal dorsal horn and implicate a role for CB(2) and CB(1) in peripheral cannabinoid modulation of inflammatory nociception. Expand
Control of pain initiation by endogenous cannabinoids
TLDR
It is shown that anandamide attenuates the pain behaviour produced by chemical damage to cutaneous tissue by interacting with CB1-like cannabinoid receptors located outside the CNS, and that locally generated an andamide and PEA may mediate this effect. Expand
CB(1) cannabinoid receptor stimulation modulates transient receptor potential vanilloid receptor 1 activities in calcium influx and substance P Release in cultured rat dorsal root ganglion cells.
TLDR
It is suggested that CB(1) could inhibit either the capsaicin-induced Ca(2+) influx or the potentiation of capsaicIn-induced SPLI release by a long-term treatment with bradykinin through involvement of a cyclic-AMP-dependent PKA pathway. Expand
Local administration of Δ9-tetrahydrocannabinol attenuates capsaicin-induced thermal nociception in rhesus monkeys: a peripheral cannabinoid action
TLDR
Functional evidence is provided that activation of peripheral cannabinoid CB1 receptors can attenuate capsaicin-induced thermal nociception in non-human primates and suggests a new approach for cannabinoids in pain management. Expand
Cannabinoids against pain. Efficacy and strategies to reduce psychoactivity: a clinical perspective.
TLDR
An overview of the endocannabinoid system, its components and functions and the current approaches to avoiding cannabimimetic side effects by separating them from the therapeutic effects are explained. Expand
...
1
2
3
4
...